Antiglaucoma Drugs Global Market Report 2024

The antiglaucoma drugs market size has grown strongly in recent years. It will grow from $15.07 billion in 2023 to $16.27 billion in 2024 at a compound annual growth rate (CAGR) of 7.9%. The growth observed during the historical period can be attributed to several key factors, including the aging population, rising awareness about glaucoma, increasing healthcare expenditure, and regulatory approvals for antiglaucoma drugs. These factors have collectively contributed to the expansion of the antiglaucoma drug market.

The antiglaucoma drugs market size is expected to see strong growth in the next few years. It will grow to $21.9 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. In the forecast period, the antiglaucoma drugs market is expected to grow due to emerging markets, reimbursement policies, and disease awareness campaigns. Major trends include technological advancements, innovation, telemedicine, biologics, sustained-release formulations, and sustainability.

The incidence of glaucoma tends to increase with age, and as the global population ages, governments around the world are launching initiatives to raise awareness about glaucoma and other eye disorders. An example of such an initiative is the Vision Health program initiated by the Centers for Disease Control and Prevention (CDC) in the United States, which focuses on preventing eye disorders, including glaucoma, and improving overall eye health. Furthermore, in July 2021, the United Nations General Assembly passed a resolution emphasizing the need to expand eye care services within universal health coverage. The resolution aimed to address the adverse impacts of vision loss on sustainable development, particularly due to conditions like short and farsightedness, glaucoma, and cataracts. These government initiatives are expected to increase awareness among the public about glaucoma, which, in turn, will drive the market for antiglaucoma drugs.

The primary categories of antiglaucoma drugs include alpha agonists, beta-blockers, prostaglandin analogs, combined medications, and other related products. Alpha-adrenergic agonists are a class of sympathomimetic drugs that selectively activate alpha-adrenergic receptors. These antiglaucoma products are available through both hospital prescriptions and over-the-counter channels and are utilized to manage various types of glaucoma, including open-angle glaucoma, angle-closure glaucoma, normal-tension glaucoma, congenital glaucoma, and other forms of the condition.

The antiglaucoma drug market research report is one of a series of new reports that provides antiglaucoma drug market statistics, including antiglaucoma drug industry global market size, regional shares, competitors with an antiglaucoma drug market share, detailed antiglaucoma drug market segments, market trends and opportunities, and any further data you may need to thrive in the antiglaucoma drug industry. This antiglaucoma drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The rising prevalence of myopia is expected to drive the growth of the antiglaucoma drugs market in the future. Myopia is a refractive eye condition characterized by clear vision of nearby objects but difficulty focusing on distant objects. Antiglaucoma drugs have proven to be an effective therapy for managing myopia progression and refractive regression in patients, reducing the need for ophthalmic surgeries. For instance, in December 2022, as reported by NVISION Eye Centers, a US-based medical practice company specializing in eye care, approximately 34 million people in the United States were expected to have myopia in 2022. Furthermore, a May 2022 report from the Brien Holden Vision Institute, an Austria-based nonprofit organization, projected that by 2050, half of the global population will experience myopia, with an estimated 5 billion individuals suffering from preventable vision loss. As a result, the increasing prevalence of myopia is a significant driver of growth in the antiglaucoma drugs market.

Anti-glaucoma drugs are confronted with the risk of patent expirations in the United States and Europe. Notably, medications such as travoprost and bimatoprost, commonly used for treating glaucoma, have lost their patent protection in 2021. Consequently, this has led to the introduction of generic versions of these drugs, which are typically priced lower than their branded counterparts. The availability of lower-priced generic alternatives poses a challenge to the overall growth of the antiglaucoma drug market, as it can lead to increased competition and potential revenue reductions for branded products.

Companies in the antiglaucoma drugs market are actively developing combination therapies for the treatment of glaucoma, as these therapies have shown the ability to effectively lower intraocular pressure in glaucoma patients. Many of these combination therapies are formulated as fixed-dose drugs, offering patients the convenience of consuming multiple active ingredients in a single formulation. For instance, Alcon introduced Simbrinza, a fixed combination drug that combines Brinzolamide and Brimonidine. This product is designed to help patients reduce the need for multiple individual drugs in the treatment of glaucoma. Other examples include Rockland, a combination of a rho kinase inhibitor and a prostaglandin analog, Combigan, which combines beta blockers and alpha agonists, and Cosopt, a combination of beta-blockers and carbonic anhydrase inhibitors. These combination therapies provide glaucoma patients with effective treatment options that streamline their medication regimens.

Major companies in the antiglaucoma drug market are dedicated to innovation, developing new products to better serve their customers. One such innovative product is OMLONTI (Omidenepag Isopropyl Ophthalmic Solution), which is administered as an antiglaucoma eye drop treatment, particularly effective for open-angle glaucoma. For instance, in September 2022, Santen Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, collaborated with UBE Corporation, a Japan-based chemical company, to launch OMLONTI (Omidenepag Isopropyl Ophthalmic Solution), which received approval from the US Food and Drug Administration (FDA). OMLONTI is in the form of eye drops and is employed for reducing elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension. It is unique in its pharmacological action, as it is a selective prostaglandin EP2 receptor agonist, making it the only product with this distinct mechanism of action in the market. This kind of innovation demonstrates the commitment of these companies to delivering improved treatment options in the antiglaucoma drug market.

To obtain approval from the United States Food and Drug Administration (USFDA) for an antiglaucoma drug, the drug needs to demonstrate comparable intraocular pressure (IOP) lowering efficacy and a favorable benefit-to-risk ratio in comparison to established benchmark drugs used for the treatment of glaucoma. An example of such an approval is Rhopressa (netarsudil) Ophthalmic Solution, developed by Aerie Pharmaceuticals Inc. This drug received US FDA approval based on its ability to effectively lower IOP when compared to the benchmarked drugs already available for the treatment of glaucoma in the market. This stringent evaluation ensures that new antiglaucoma drugs meet the required standards for safety and efficacy.

Major companies operating in the antiglaucoma drugs market include Aerie Pharmaceuticals Inc., Allergan Inc., Novartis AG, Abbott Healthcare Pvt. Ltd., Johnson & Johnson, Merck & Co., Genentech Inc., Pfizer Inc., Bayer AG, Santen Pharmaceuticals Company Ltd., Regeneron Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., F. Hoffmann-La Roche Ltd., Hoya Corporation, Bausch + Lomb Inc., Fera Pharmaceuticals LLC, Thea Pharma Inc., Alcon AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Akorn Inc., Mylan Pharmaceuticals Pvt. Ltd., Apotex Inc., Lupin Pharmaceuticals Inc., Wockhardt Ltd., Zydus Pharmaceuticals Inc., Cooper Laboratories Inc., Cooper Pharma Ltd., Rafarm SA, Altaire Pharmaceuticals Inc.

North America was the largest region in the antiglaucoma drugs market in 2023. Middle East is expected to be the fastest-growing region in the antiglaucoma drugs market during the forecast period. The regions covered in the antiglaucoma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the antiglaucoma drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The antiglaucoma drug market consists of sales of dipivefrin, epinephrine, and apraclonidine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.